Enlaza Therapeutics
A USA-based biotech company developing the first covalent biologic platform.
In May 2024, Enlaza announced a $100 million Series A financing, with proceeds being used to develop Enlaza’s proprietary covalent protein technologies and to support advancement of wholly owned pipeline programs to the clinic.
The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding.
Latest Enlaza Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze